Table 4.
Relationship between MAP, eGFR, proteinuria, and other clinical variables
| Characteristic | MAP (mm Hg) No. of evaluable patients (%) |
P value | eGFR (ml/min per 1.73 m2) No. of evaluable patients (%) |
P value | Proteinuria (g/d) No. of evaluable patients (%) |
P value | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| <104 (111/201 (55.2)) | ≥104 (90/201 (44.8)) | >59.9 (62/201 (30.8)) | 30-59.9 (78/201 (38.8)) | <30 (61/201 (30.3)) | <1 (49/200 (24.5%)) | 1-2.99 (84/200 (42%)) | >3 (67/200 (33.5%)) | ||||
| Age, yr, mean±SD | 35.97±11 | 36.04±8.7 | ns | 31.29±8.23 | 37.91±9.76 | 38.36±10.53 | <0.001a,b | 34.08±11.35 | 36.45±10 | 37.04±8.86 | ns |
| Gender, male-female, n (ratio) | 73:38 (1.9:1) | 69:21 (3.3:1) | 0.06 | 40:22 (1.8:1) | 58:20 (2.9:1) | 44:17 (2.58:1) | ns | 27:22 (1.2:1) | 65:19 (3.4:1) | 50:17 (2.9:1) | 0.017 |
| BMI, mean±SD | 24.62±3.7 | 24.99±4.5 | ns | 25.71±4.4 | 24.5±4.3 | 24.22±3.1 | ns | 24.85±3.73 | 24.58±3.83 | 25.07±4.55 | ns |
| Systolic BP, mm Hg, mean±SD | 125.68±12.7 | 154.27±16.6 | <0.001 | 132±17.0 | 138.67±18.28 | 144.84±23.86 | 0.04a<0.001b | 130.69±18.18 | 137±19.14 | 146.16±21.03 | <0.001b, 0.006c |
| Diastolic BP, mm Hg, mean±SD | 77.94±6 | 97.48±9.8 | <0.001 | 84.48±11.3 | 87.47±11 | 88±15.3 | ns | 82.55±11.53 | 85.29±11.17 | 91.57±13.57 | <0.001b, 0.002c |
| MAP, mm Hg, mean±SD | 93.85±7.1 | 116.41±10.8 | <0.001 | 100.32±12.51 | 104.54±12.6 | 106.89±17.3 | 0.01b | 98.6±13.16 | 102.52±13.06 | 109.77±14.94 | <0.001b, 0.002c |
| BP ≥140/90 mm Hg, n yes (%) | 22 (20) | 88 (97.8) | <0.001 | 26 (41.9) | 44 (56.4) | 40 (65.6) | 0.037 | 16 (32.7) | 43 (51.2) | 51 (76.1) | <0.001 |
| Hemoglobin, g/dl, mean±SD | 12±2.1 | 12.3±2.1 | ns | 13.04±1.9 | 12.3±1.8 | 10.9±2 | 0.01a, <0.001b,c | 12.6±2.24 | 12.18±1.98 | 11.69±1.99 | 0.02b |
| Serum total protein, g/dl, mean±SD, n | 6.86±0.7 | 6.83±0.7 | ns | 7.05±0.84 (60) | 6.97±0.62 (76) | 6.6±0.57 (62) | 0.001b,c | 7.32±0.52 (48) | 6.96±0.62 (82) | 6.4±0.65 (67) |
0.001a <0.001b,c |
| Serum albumin, g/dl, mean±SD, n | 3.94±0.6 | 3.98±0.5 | ns | 3.99±0.7 (60) | 4.06±0.48 (76) | 3.79±0.45 (62) | 0.04b, 0.007c | 4.35±0.36 (48) | 4.06±0.44 (82) | 3.57±0.54 (67) |
0.001a <0.001b,c |
| 24-hour urine protein, g/d, median (IQR) | 1.55 (0.8–2.8) | 2.54 (1.4–4.4) | 0.001 | 1.2 (0.6–2.54) | 1.79 (1–3.5) | 3.1 (1.7–4.8) | <0.001b, 0.002c | 0.55 (0.30–0.82) | 1.74 (1.36–2.28) | 4.6 (3.7–5.9) | <0.001a,b,c |
| Serum total cholesterol, mg/dl, mean±SD | 171.64±62.4 | 183.29±49.5 | ns | 185.53±72.86 (60) | 182.86±50.22 (76) | 160.37±42.37 (62) | 0.01b,c | 151.38±37.12 (48) | 171.11±46.56 (83) | 200.88±69.5 (48) | <0.001b, 0.001c |
| Serum uric acid, mg/dl, mean±SD | 6.62±1.8 | 7.51±1.8 | 0.001 | 6.2±1.48 (60) | 7.52±1.9 (78) | 7.23±1.94 (61) | <0.001a, 0.003b | 6.5±1.98 (49) | 7.05±1.9 (82) | 7.39±1.7 (67) | 0.02b |
| Serum creatinine, mg/dl, mean±SD | 1.9±1 | 2.4±1.1 | 0.003 | 1.02±0.29 | 1.96±0.36 | 3.39±0.76 | <0.001a,b,c | 1.53±0.82 | 2.15±1.06 | 2.50±1.05 |
0.001a, <0.001b 0.04c |
| eGFR, ml/min per 1.73 m2, median (IQR) | 44 (29–80) | 36 (24–54.3) | 0.009 | 89.5 (72.8–114.5) | 40 (33–47) | 21 (16–24) | <0.001a,b,c | 59 (36–107.5) | 43 (28.25–64) | 30 (22–42) | <0.001a,b |
eGFR, estimated glomerular filtration rate (calculated using the CKD-EPI [Chronic Kidney Disease Epidemiology Collaboration] formula); BMI, body mass index; BP, blood pressure; MAP, mean arterial pressure; SD, standard deviation.
One-way analysis of variance was used for comparisons between 3 or more groups and the t Test with Fisher Least Significant Difference was used to test significance between groups. P value was significant at 0.05 between acolumns 1 and 2, bcolumns 1 and 3, and ccolumns 2 and 3 columns.